Subunit vaccine for treatment or prevention of a respiratory tract infection

Inventors

Perugi, Fabien • Schwamborn, Klaus • Schüler, Wolfgang • Lundberg, Urban • Meinke, Andreas

Assignees

Valneva SE

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12162909-B2

Patent

Publication Date

2024-12-10

Expiration Date


Abstract

The present invention relates to modified hMPV F proteins stabilized in the pre-fusion conformation as vaccine candidates.

Core Innovation

The invention describes an immunogenic, modified human metapneumovirus (hMPV) F protein in a pre-fusion-stabilized form comprising a recombinant single-chain polypeptide that lacks a fusion peptide and contains F2 and F1 domains. The polypeptide comprises or consists of SEQ ID NO: 56 or a variant with at least 99% sequence identity. A short linker positioned between the domains contains a cysteine residue that forms a disulfide bond with a non-natural cysteine residue in the F1 domain.

The described constructs exhibit prefusion antigenicity, immunogenicity, and protective efficacy against hMPV challenge. Recombinant candidates demonstrate preferential binding to the pre-fusion-specific MPE8 antibody over the post-fusion-specific MF1 antibody. Reported evaluations document neutralizing antibodies, reduced lung viral loads and lower infectious-virus levels relative to placebo groups, and protection across tested constructs, adjuvants, and doses.

Claims Coverage

The claims cover one independent claim comprising three inventive features.

Fusion-peptide-lacking single-chain hMPV F protein

An immunogenic modified human metapneumovirus (hMPV) F protein comprising a recombinant single-chain polypeptide lacking a fusion peptide and containing F2 and F1 domains.

Specified polypeptide sequence

The recombinant single-chain polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 56 or a variant having at least 99% sequence identity thereto.

Linker forming a disulfide bond

A linker positioned between the F2 and F1 domains is 1 to 10 amino acids in length and contains a cysteine residue that forms a disulfide bond with a non-natural cysteine residue present in the F1 domain.

The independent claim covers an immunogenic modified hMPV F protein having a fusion-peptide-lacking single-chain F2–F1 structure, specified sequence identity, and a short cysteine-containing interdomain linker that forms the specified disulfide bond.

Stated Advantages

The recombinant candidates demonstrate prefusion antigenicity by preferentially binding the pre-fusion-specific MPE8 antibody over the post-fusion-specific MF1 antibody.

Studies report immunogenicity and neutralizing antibodies, yielding reduced lung viral load and lower lung infectious-virus levels compared to placebo groups following viral challenge across tested constructs, adjuvants, and doses.

Documented Applications

Use as an hMPV vaccine candidate or within an immunogenic composition.

Administration of the immunogenic modified F protein to generate an immune response and to treat or prevent a respiratory tract infection in a human subject.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.